A 42-year-old man comes to the clinic for initiation of pharmacotherapy for recently diagnosed active pulmonary tuberculosis. Sputum acid-fast bacilli smears were positive, and nucleic acid amplification testing confirmed Mycobacterium tuberculosis. He has a history of type 2 diabetes mellitus but is otherwise healthy. A standard four-drug regimen consisting of isoniazid, rifampin, pyrazinamide, and ethambutol is planned. Which of the following baseline evaluations MUST be documented prior to starting and monitored during this specific regimen? (Select all that apply)
- Hepatic aminotransferases and bilirubinAnswer
- Visual acuity and color discrimination testingAnswer
- CHigh-frequency audiometry
- DElectrocardiography with QTc interval measurement
- EThyroid-stimulating hormone level
Answer
The required evaluations are hepatic aminotransferases and bilirubin, as well as visual acuity and color discrimination testing.
The standard four-drug regimen for active tuberculosis includes isoniazid, rifampin, pyrazinamide, and ethambutol. Three of these agents (isoniazid, rifampin, and pyrazinamide) are potentially hepatotoxic, necessitating a baseline hepatic panel (aminotransferases, bilirubin, and alkaline phosphatase) and ongoing symptom-driven or periodic monitoring. Ethambutol can cause dose-dependent optic neuritis, which typically presents as diminished visual acuity and loss of red-green color discrimination; therefore, baseline visual acuity (e.g., Snellen chart) and color discrimination (e.g., Ishihara plates) testing are mandatory prior to initiation.
Step-by-Step Solution
Key Concept
Monitoring parameters for high-risk pharmacotherapies (First-line Anti-Tuberculosis Regimen)